All Oncology News

Nathan Bahary, MD, PhD, a medical oncologist, was most recently the medical director of the Pancreatic Cancer Program, co-director of the UPMC Pancreatic Cancer Center of Excellence, and co-director of the UPMC Phase II program.

The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.

The armamentarium of multiple myeloma has expanded with the introduction of combination regimens in the up-front setting and novel targeted agents, including CAR T-cell therapy, in the relapsed/refractory setting.

A biologics license application seeking the approval of teclistamab for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.

The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.

American Oncology Network, LLC is pleased to announce that eight research studies co-authored by AON physicians were presented at the American Society of Hematology Annual Meeting & Exposition, held December 11-14, 2021.

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.

Data from key clinical trials evaluating expanded combination strategies and novel therapies have transformed the treatment paradigms of newly diagnosed, relapsed/refractory, and heavily pretreated multiple myeloma, but it remains important to contextualize the data appropriately without cross-trial comparisons.

Syma Iqbal, MD, shares the main highlights from an IPC meeting, which centered on the evolving landscapes and importance of implementing best practices for patients with hepatobiliary cancers, locally advanced and advanced pancreatic cancer, advanced gastric/gastroesophageal junction cancer, and metastatic colorectal cancer.

Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.

Immune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.

Stephen Johnston, MD, PhD, provides insight on the effect the approval of the CDK4/6 inhibitor abemaciclib has for patients with early breast cancer and how it will advance investigative efforts in this space.

The FDA has granted Fast Track Designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the potential treatment of patients with acute myeloid leukemia.

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts shared their insights on the most recent FDA-approved agents for MDS, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020.

Peter Schmid, MD, PhD, discussed how this approval defines a new standard of care for patients with TNBC.

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

Leslie S. Kersun, MD, MSCE, MSEd, discusses finding the right fellowship program; the challenge of balancing research, patient care, and education as a trainee; and finding one’s focus during fellowship.

A little self-reflection and a lot of self-compassion go a long way in a world of immense change.

With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer.

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.

MUSC Hollings Cancer Center researchers hope to save lives by expanding the Tobacco Treatment Program, first implemented at MUSC Health in 2014, to rural and underserved communities to improve overall patient health, save patients money and reduce the number of premature deaths.

Zandelisib demonstrated significant activity and an encouraging preliminary safety profile in patients with relapsed/refractory follicular lymphoma who have received at least 2 prior systemic therapies.

Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate HER2-directed bispecific antibodies in HER2-positive breast cancer, the emergence of zanidatamab as a potential treatment strategy, and the unmet medical need the agent could fill in this disease.

The FDA has granted a breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR-mutated non–small cell lung cancer with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.

James P. Allison, PhD, permanently etched his legacy into immuno-oncology with the development of ipilimumab, work that helped him win a Giants of Cancer Care® award for Scientific Advances in 2014.

Frontline nivolumab plus ipilimumab showcased improved overall survival over chemotherapy and a trend toward improved intracranial progression-free survival and duration of response in patients with advanced non–small cell lung cancer.

Evan J. Lipson, MD, discusses the role of ctDNA in the neoadjuvant, adjuvant, and metastatic settings in the realm of melanoma, remaining questions with this marker, and future directions to optimize its use in this disease.

Lee S. Schwartzberg, MD, discusses the culmination of research with androgen-targeted agents in metastatic androgen receptor–positive, estrogen receptor–positive breast cancer and ongoing research that could lead to a paradigm shift in the second-line setting.

A new drug application has been submitted to the FDA seeking the marketing approval of dovitinib as a potential option in the third-line treatment of patients with renal cell carcinoma.